Discovery of NXT-10796, an orally active, intestinally restricted EP4 agonist prodrug for the treatment of inflammatory bowel disease

Publication date: 15 July 2023Source: Bioorganic & Medicinal Chemistry Letters, Volume 91Author(s): Miguel St.-Onge, Amandine Chefson, Joyce Wu, Édouard Caron-Duval, Valerie Dumais, Stephane Dorich, Jennifer Cox, Alex Caron, Jason Burch, M. David Perci…